Helport AI Opens Thailand Office 
playX Receives the ‘Enterprise Award’ at the Asia Golden Star Awards in Tokyo 
Zhibao Technology Announces Receipt of Nasdaq Deficiency Letter 
Fairfax County and Penzance Officials Break Ground on Next-Generation Digital Infrastructure Project to Power the World’s Deep Tech Future Northern Superior Resources Closes Non-Brokered Private Placement:
C$6.65 Million Raised, Upsized From Initial C$3.00 Million Offering Board Member Participation Cree First Nation…
EV Nickel Inc. Update On Corporate Activity
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN…
This Week on MoneyTV with Donald Baillargeon, 12/3
HOLLYWOOD, CA / ACCESSWIRE / December 3, 2021 / Cancer research, solar growth, cannabis space,…
EonX Technologies Inc. Signs Agreement with Mastercard Priceless to Deliver New Customer Experience & Loyalty Solution
TORONTO, ON / ACCESSWIRE / December 3, 2021 / EonX Technologies Inc. (CSE:EONX), (“EonX” or…
American Manganese Files National Phase Patent Applications for the RecycLiCo Lithium-ion Battery Recycling Process
Applications Filed into National Phase for Europe, South Korea, Canada, India, Australia, Japan, and China…
Founder of Become A Living God, E.A. Koetting, Announces New Collaborative Works
The flagship author of Become A Living God kicks off a new series of cooperative…
Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study
Press Release Stockholm, Sweden, December 3, 2021 Immunicum Announces Completion of Phase Ib Portion and…
ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
ORION CORPORATION STOCK EXCHANGE RELEASE / INSIDE INFORMATION3 DECEMBER 2021 at 8.30 EETÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â ARASENS trial…
Bone Therapeutics Successfully Raises EUR 3.3 Million in Private Placement
REGULATED INFORMATION NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR…
Roche has rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant
Roche subsidiary TIB Molbiol rapidly developed additional testing options to differentiate mutations in the Omicron…
HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Addition of SULANDA® in the National Reimbursement Drug List in China
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 03, 2021 (GLOBE NEWSWIRE) —…
Psyence Group Announces Private Placement
TORONTO, Dec. 02, 2021 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the…
Talis Biomedical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a…
Saniona Chairman J. Donald deBethizy and CEO Rami Levin, as well as additional members of the board and management, purchase Saniona shares in the open market
PRESS RELEASE December 2, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on…
Zogenix To Present New FINTEPLA® (fenfluramine) Data at AES 2021
Data add to the growing body of evidence supporting the efficacy and safety profile of…
Medexus to Participate in Two Upcoming Virtual Investor Conferences
TORONTO and CHICAGO, Dec. 02, 2021 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”)…
Lyell Immunopharma Announces Return of Dr. Rick Klausner as Board Chair
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Lyell), (Nasdaq:…
Enzo Biochem to Report First Quarter 2022 Financial Results and Business Update on Wednesday, December 15th
Conference Call and Webcast Scheduled for December 15, 2021, 4:30 pm ET NEW YORK, NY,…
Context Therapeutics® Reports Third Quarter 2021 Operating and Financial Results
Entered into $31.25 million Private Placement Agreement Completed Initial Public Offering of Common Stock and…
Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma
Designation covers UV1 in Metastatic Melanoma as sole agent or part of combination Seven-year market…